人才队伍

1.Sun YL,  Chen MM,  Han YY,  Li  WQ,  Ma XY,  Shi ZH, Zhou Y,  Xu  L, Yu L, Wang YX, Yu JY, Diao XX4 , Meng LH*,  Xu SL*.  Discovery of Pyrido[2,3- d]pyrimidin-7-one Derivatives as Highly Potent and Efficacious Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Cancer Treatment. J Med Chem 2024 Feb 22. doi: 10.1021/acs.jmedchem.3c02288.

2.Zhang X, Wang YX, Zhang X, Shen YY, Yang K, Ma QY, Qiao YM, Shi JJ, Wang Y, Xu L Yang BY, Ge GX, Hu LD, Kong XY, Yang CH, Chen Y*, Ding J*, Meng LH*. Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors. Signal Transduct Target Ther. 2023;8(1):153.

3.Chen MM, Guo W, Chen SM, Guo XZ, Xu L, Ma XY, Wang YX, Xie C, Meng LH*. Xanthine dehydrogenase rewires metabolism and the survival of nutrient deprived lung adenocarcinoma cells by facilitating UPR and autophagic degradation. Int J Biol Sci 2023;19(3):772-788.

4.Xing H, Gao MS, Wang YX, Zhang X, Shi J, Wang X, Liu X, Ma Q, Kong X, Yang C, Ding J*, Meng L*. Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in esophageal squamous cell carcinoma. Clin Transl Med. 2022;12:e835

5.Zhang X, Wang YX, Meng L*. Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy. Acta Pharmaceutica Sinica B. 2022; 12( 3): 1054-1067

6.Chen ZQ, Cao ZR, Wang Y, Zhang X, Xu L, Wang YX, Chen Y, Yang CH, Ding J*, Meng LH*. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma. Cancer Lett. 2022 ;524:206-218.

7.Sun P, Zhang X, Wang RJ, Ma QY, Xu L, Wang Y, Liao HP, Wang HL, Hu LD, Kong X*, Ding J*, Meng LH*. PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8 + T cells and promoting fatty acid metabolism. J Immunother Cancer. 2021; 9(8):e003093. 

8.Wang YX, Zhang X, Ma QY, Hu LD, Zhang X, Wang Y, Xu L, Yang CH, Tan C, Kong XY, Ding J*, Meng LH*. Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cell. Cell Death Dis. 2021;12(1):85. 

9.Liu XL, Wang BB, Wang Y, Wang YX, Yang CH, Tan C, Zhang X, He QJ, Ding J*, Meng LH*. Unbiased screening reveals that blocking exportin 1 overcomes resistance to PI3Kα inhibition in breast cancer. Signal Transduct Target Ther. 2019 Nov 22;4:49.

10.Shi JJ, Xing H, Wang YX , Zhang X, Zhan QM, Geng MY, Ding J*, Meng LH*. PI3Kα Inhibitors Sensitize Esophageal Squamous Cell Carcinoma to Radiation by Abrogating Survival Signals in Tumor Cells and Tumor Microenvironment. Cancer Lett. 2019;459:145-155